ATE403650T1 - 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren - Google Patents

2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren

Info

Publication number
ATE403650T1
ATE403650T1 AT04780055T AT04780055T ATE403650T1 AT E403650 T1 ATE403650 T1 AT E403650T1 AT 04780055 T AT04780055 T AT 04780055T AT 04780055 T AT04780055 T AT 04780055T AT E403650 T1 ATE403650 T1 AT E403650T1
Authority
AT
Austria
Prior art keywords
chinoxalin
ylsulfonylamino
benzamide compounds
cck2
modulators
Prior art date
Application number
AT04780055T
Other languages
English (en)
Inventor
Brett Allison
Michael Hack
Victor Phuong
Michael Rabinowitz
Mark Rosen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE403650T1 publication Critical patent/ATE403650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04780055T 2003-08-08 2004-08-04 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren ATE403650T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08

Publications (1)

Publication Number Publication Date
ATE403650T1 true ATE403650T1 (de) 2008-08-15

Family

ID=34193199

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04780056T ATE353322T1 (de) 2003-08-08 2004-08-04 Verfahren zur herstellung von 2- (chinoxalin-5- ylsulfonylamino) -benzamid-verbindungen
AT04780055T ATE403650T1 (de) 2003-08-08 2004-08-04 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04780056T ATE353322T1 (de) 2003-08-08 2004-08-04 Verfahren zur herstellung von 2- (chinoxalin-5- ylsulfonylamino) -benzamid-verbindungen

Country Status (33)

Country Link
US (3) US7304051B2 (de)
EP (2) EP1651621B1 (de)
JP (2) JP2007501842A (de)
KR (1) KR20060060007A (de)
CN (2) CN1863781A (de)
AR (1) AR045930A1 (de)
AT (2) ATE353322T1 (de)
AU (2) AU2004265311A1 (de)
BR (1) BRPI0413449A (de)
CA (2) CA2534885C (de)
CR (1) CR8229A (de)
CY (1) CY1106486T1 (de)
DE (2) DE602004015614D1 (de)
DK (2) DK1651622T3 (de)
EA (1) EA200600203A1 (de)
EC (1) ECSP066355A (de)
ES (2) ES2281834T3 (de)
HR (1) HRP20080559T3 (de)
IL (1) IL173591A0 (de)
IS (1) IS8280A (de)
LT (1) LT5410B (de)
LV (1) LV13453B (de)
MX (2) MXPA06001550A (de)
NO (1) NO20061122L (de)
NZ (1) NZ545030A (de)
PL (2) PL1651622T3 (de)
PT (2) PT1651621E (de)
SG (1) SG131114A1 (de)
SI (2) SI1651622T1 (de)
TW (1) TW200521120A (de)
UA (1) UA84025C2 (de)
WO (2) WO2005016896A1 (de)
ZA (1) ZA200601946B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651621B1 (de) * 2003-08-08 2008-08-06 Janssen Pharmaceutica N.V. 2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
US7297816B2 (en) 2004-09-24 2007-11-20 Janssen Pharmaceutica N.V. Sulfonamide compounds
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
EP2123644B1 (de) 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepin-derivate und deren anwendung
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131244A3 (de) * 2008-06-02 2012-04-11 ASML Netherlands BV Lithografische Vorrichtung und Verfahren zur Messung von Mustereigenschaften
WO2009154754A2 (en) * 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
ES2529233T3 (es) 2010-07-09 2015-02-18 Convergence Pharmaceuticals Limited Compuestos tetrazol como bloqueadores de canales de calcio
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
ES2791534T3 (es) 2012-03-01 2020-11-04 Allergan Inc Derivados de benzofuran-2-sulfonamida como moduladores del receptor de quimiocinas
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
RU2693484C1 (ru) 2013-11-22 2019-07-03 СиЭль БАЙОСАЕНСИЗ ЭлЭлСи Антагонисты гастрина для лечения и профилактики остеопороза
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用
WO2025224201A1 (en) 2024-04-26 2025-10-30 F. Hoffmann-La Roche Ag Novel process for the synthesis of substituted morpholines and thiomorpholines
CN118878477B (zh) * 2024-05-31 2025-09-23 上海馨远医药科技有限公司 一种手性r或s的3-甲基吗啉的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
PL181782B1 (pl) * 1993-08-10 2001-09-28 Black James Foundation Nowe zwiazki i sposób wytwarzania nowych zwiazków PL
JP3999819B2 (ja) 1996-12-10 2007-10-31 ゼリア新薬工業株式会社 1,5―ベンゾジアセピン誘導体
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
EP1651621B1 (de) * 2003-08-08 2008-08-06 Janssen Pharmaceutica N.V. 2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren
US7297816B2 (en) * 2004-09-24 2007-11-20 Janssen Pharmaceutica N.V. Sulfonamide compounds

Also Published As

Publication number Publication date
EA200600203A1 (ru) 2006-08-25
DK1651622T3 (da) 2007-05-07
JP4818110B2 (ja) 2011-11-16
MXPA06001482A (es) 2006-09-04
DE602004004663T2 (de) 2007-11-22
EP1651622B1 (de) 2007-02-07
JP2007501842A (ja) 2007-02-01
SI1651622T1 (sl) 2007-06-30
ZA200601946B (en) 2007-05-30
IL173591A0 (en) 2006-07-05
CA2534885C (en) 2013-06-04
CA2534885A1 (en) 2005-02-24
PL1651621T3 (pl) 2009-01-30
KR20060060007A (ko) 2006-06-02
EP1651621A1 (de) 2006-05-03
AR045930A1 (es) 2005-11-16
EP1651621B1 (de) 2008-08-06
US20050038032A1 (en) 2005-02-17
US7288651B2 (en) 2007-10-30
US20080076918A1 (en) 2008-03-27
NO20061122L (no) 2006-05-04
PL1651622T3 (pl) 2007-07-31
DK1651621T3 (da) 2008-11-10
DE602004015614D1 (de) 2008-09-18
LV13453B (en) 2007-02-20
ECSP066355A (es) 2006-08-30
US20050043310A1 (en) 2005-02-24
US7304051B2 (en) 2007-12-04
CY1106486T1 (el) 2012-01-25
IS8280A (is) 2006-01-31
ATE353322T1 (de) 2007-02-15
PT1651621E (pt) 2008-09-30
AU2004265312A1 (en) 2005-02-24
WO2005016897A1 (en) 2005-02-24
SG131114A1 (en) 2007-04-26
CR8229A (es) 2008-09-10
LT2006017A (en) 2006-11-27
TW200521120A (en) 2005-07-01
MXPA06001550A (es) 2006-09-04
NZ545030A (en) 2009-08-28
WO2005016896A1 (en) 2005-02-24
HRP20080559T3 (hr) 2009-01-31
AU2004265311A1 (en) 2005-02-24
ES2281834T3 (es) 2007-10-01
CA2534887A1 (en) 2005-02-24
AU2004265312B2 (en) 2010-05-20
UA84025C2 (en) 2008-09-10
ES2310294T3 (es) 2009-01-01
EP1651622A1 (de) 2006-05-03
BRPI0413449A (pt) 2006-10-17
US7563895B2 (en) 2009-07-21
SI1651621T1 (sl) 2008-12-31
JP2007501841A (ja) 2007-02-01
DE602004004663D1 (de) 2007-03-22
CN1863781A (zh) 2006-11-15
LT5410B (lt) 2007-03-26
PT1651622E (pt) 2007-04-30
CN1863782A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
DE602004015614D1 (de) 2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren
SE0302305D0 (sv) Novel Compounds
NO20054005D0 (no) Nye arylpiperazinylforbindelser
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8108A (is) Ný efnasambönd
NO20054310D0 (no) Polyetylenglykolbundede GLP-1-forbindelser
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
IS8323A (is) Ný amínóbensófenónefnasambönd
IS7471A (is) Ný efnasambönd
NO20052928D0 (no) Nye kjemiske forbindelser
IS8228A (is) Ný asetídínefnasambönd
NO20045659L (no) Forbindelser
DE602004006997D1 (de) 4-(aminomethyl)-piperidinbenzamide als 5ht4 -antagonisten
IS7827A (is) Ný efnasambönd
IS8292A (is) Ný efnasambönd
NO20055750D0 (no) Nye kjemiske forbindelser
SE0303452D0 (sv) New compounds
SE0203348D0 (sv) Novel compounds
SE0300388D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
SE0302667D0 (sv) Novel Compounds
SE0201636D0 (sv) Novel compounds
SE0203822D0 (sv) Novel compounds
SE0201857D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1651621

Country of ref document: EP

REN Ceased due to non-payment of the annual fee